Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY„¢ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will present at the following upcoming conferences:

Cowen & Company 39th Annual Health Care Conference Date: Wednesday, March 13, 2019 Presentation Time: 10:40 a.m. ET Speaker: Mark Iwicki, Chairman, President and Chief Executive Officer Location: Boston, MA

Oppenheimers 29th Annual Healthcare Conference Date: Wednesday, March 20, 2019 Presentation Time: 8:35 a.m. ET Speaker: Todd Bazemore, Chief Operating Officer Location: New York, NY

To access a live webcast and subsequent archived recording of each presentation, please visit the Investors & Media section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the United States Food and Drug Administration (FDA) and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.

Investor Contact:
Michael Schaffzin, 212-362-1200
[email protected]
or
Media
Contact:
Kari Watson, 781-235-3060
[email protected]